Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA493586
Max Phase: Preclinical
Molecular Formula: C16H16O10
Molecular Weight: 368.29
Molecule Type: Small molecule
Associated Items:
ID: ALA493586
Max Phase: Preclinical
Molecular Formula: C16H16O10
Molecular Weight: 368.29
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 4-Methylumbelliferone Glucuronide
Synonyms from Alternative Forms(1):
Canonical SMILES: O=C(O)[C@H]1O[C@@H](OCc2cc(=O)oc3cc(O)ccc23)[C@H](O)[C@@H](O)[C@@H]1O
Standard InChI: InChI=1S/C16H16O10/c17-7-1-2-8-6(3-10(18)25-9(8)4-7)5-24-16-13(21)11(19)12(20)14(26-16)15(22)23/h1-4,11-14,16-17,19-21H,5H2,(H,22,23)/t11-,12-,13+,14-,16+/m0/s1
Standard InChI Key: IHSDPYPXEDHVGB-JHZZJYKESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 368.29 | Molecular Weight (Monoisotopic): 368.0743 | AlogP: -1.09 | #Rotatable Bonds: 4 |
Polar Surface Area: 166.89 | Molecular Species: ACID | HBA: 9 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.02 | CX Basic pKa: | CX LogP: -0.95 | CX LogD: -4.60 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.42 | Np Likeness Score: 1.24 |
1. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.. (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)., 51 (11): [PMID:18457386] [10.1021/jm7015683] |
2. Hirohashi T, Suzuki H, Sugiyama Y.. (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)., 274 (1): [PMID:10329726] [10.1074/jbc.274.21.15181] |
3. Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki H, Sugiyama Y.. (1997) Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide., 282 (1): [PMID:9262353] |
4. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y.. (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics., 278 (1): [PMID:12682043] [10.1074/jbc.m212399200] |
5. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H.. (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta., 275 (1): [PMID:10660625] [10.1074/jbc.275.6.4507] |
6. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y.. (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3., 19 (1): [PMID:11837698] [10.1023/a:1013699130991] |
Source(2):